New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Mutations in MPL (thrombopoietin receptor, TPO-R) are implicated in primitive myelofibrosis (PMF).
• Recent discoveries identified MPL 515 mutations as key oncogenic drivers in PMF.
• Further investigation into novel MPL mutations in PMF is warranted.

Purpose of the Study:

• To identify and characterize novel mutations in exon 10 of the MPL gene in PMF patients.
• To determine the functional significance and transforming potential of these newly identified MPL mutations.
• To elucidate the molecular mechanisms underlying MPL-driven oncogenesis in PMF.

Main Methods:

• Systematic sequencing of MPL exon 10 in 100 PMF patients.
• Introduction of MPL mutants into Ba/F3 cells to assess gain-of-function properties.
• Evaluation of cell proliferation, tumorigenesis in nude mice, signal transduction pathway activation (JAK/STAT, RAS/MAPK, PI3K), and cell cycle progression.

Main Results:

• Seven distinct MPL mutations were identified in eight PMF patients.
• Only MPL W515 mutations demonstrated significant gain-of-function activity, including factor-independent proliferation and tumorigenesis.
• MPL W515 mutations induced spontaneous activation of JAK/STAT, RAS/MAPK, and PI3K pathways, promoting G1/S cell cycle transition.
• Other identified MPL mutations showed limited transforming activity but may cooperate with other oncogenic events like JAK2 V617F.

Conclusions:

• MPL W515 mutations are oncogenic drivers in PMF, causing spontaneous MPL activation and cell transformation.
• The identified MPL W515 mutations activate key signaling pathways crucial for myeloproliferative disorders.
• Non-W515 MPL mutations may contribute to PMF pathogenesis through synergistic interactions with other genetic alterations.